Live Breaking News & Updates on Harald Reinhart

Stay updated with breaking news from Harald reinhart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Zai Lab begins topical IL-17 trial for mild to moderate psoriasis

Zai Lab begins topical IL-17 trial for mild to moderate psoriasis
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Harald-reinhart , Kristen-dowd , Zai-lab , Lab-limited , Industry-news , Zai-lab-limited ,

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

China , United-states , Josh-smiley , Harald-reinhart , Zai-lab-forward , Zai-lab , Exchange-commission , Zai-lab-limited , Head-of-global-development , Chief-operating-officer , Global-development , Infectious-diseases

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization


China NMPA approval based on. ....

Japan , Macau , Laos , Philippines , Hong-kong , Cambodia , Taiwan , New-zealand , Vietnam , Republic-of , Indonesia , Australia

Zai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+

Zai Lab Ltd. (ZLAB) and Innoviva Specialty Therapeutics announced Monday that China's National Medical Products Administration or NMPA has approved Zai Lab's New Drug Application for XACDURO (sulbactam-durlobactam) to treat hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex in China. ....

China , Chinese , Harald-reinhart , Entasis-therapeutics-inc , China-national-medical-products-administration , Head-of-global-development , Zai-lab , Zai-lab-new-drug-application , Drug-administration , Zai-lab-ltd , More-such-health-news , World-health-organization